Pfizer Inc. (PFE) fair value analysis

S&P 500 · Updated 2026-09-07

Pfizer Inc. is a pharmaceutical and biotechnology company that develops, manufactures, and distributes prescription medications, vaccines, and consumer healthcare products across multiple therapeutic areas including oncology, immunology, cardiology, and infectious diseases. The company operates globally with research, manufacturing, and distribution facilities across North America, Europe, Asia, and other regions worldwide.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, PFE is trading at more than a 25% premium to estimated fair value.

PFE currently ranks #101 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $28.45
Sector: Healthcare
12-month range: $24.23–$28.55

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: F
Leverage: Moderate
Margin trend: Expanding
Revenue growth: Declining
RSI zone: Neutral
52-week position: The top quarter of its range
DCF cross-check: Undervalued

What our data shows for PFE

Our model validated 17 trailing price-to-earnings windows for PFE, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $24.23–$28.55.
The 14-day relative strength index sits at a neutral 65.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for PFE
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent PFE news

TickrTrends' derived news-sentiment signal for PFE is currently leaning positive, computed from recent coverage.

Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now (finance.yahoo.com, 2026-09-07)
TickrTrends take: Pfizer's valuation is currently assessed as overvalued by TickrTrends, which suggests that investors focusing on fundamental value metrics may want to examine whether near-term catalysts justify the present pricing before committing capital. For Healthcare sector investors evaluating PFE, the key consideration is whether any operational or pipeline developments cited in recent commentary can narrow the gap between current market valuation and intrinsic value estimates. Valuation-conscious readers should monitor whether PFE's fundamentals strengthen enough to support its current price levels or if the stock experiences a correction toward more historically typical valuations for the sector.
Novartis India Ltd to acquire BP drug trademarks from Pfizer Inc, for ₹1,250 crore (thehindubusinessline.com, 2026-09-07)
TickrTrends take: Pfizer's divestiture of BP drug trademarks to Novartis India represents a strategic portfolio rationalization in a competitive market segment. Given TickrTrends' current assessment that PFE is overvalued, investors should monitor whether such asset sales contribute to improved cash flow metrics or signal a broader shift in capital allocation strategy that could affect the company's valuation multiples. The transaction underscores ongoing portfolio optimization in the Healthcare sector, which typically reflects management's response to market positioning and profitability pressures on legacy product lines.
2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now (finance.yahoo.com, 2026-09-02)
TickrTrends take: Pfizer is currently rated as overvalued by TickrTrends despite being featured in analyses highlighting dividend opportunities. For investors focused on valuation metrics, this designation suggests the stock's current price may not adequately compensate for the risks involved, even if the dividend yield appears attractive on its surface. A valuation-conscious investor should monitor whether the company's earnings growth and cash flow generation justify the current market price before committing capital based primarily on dividend appeal.

What people are saying

Follow the PFE conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for PFE show that momentum status changed from A to none this week. The stock maintains an overvalued valuation verdict. This shift in momentum tracking reflects a change in the technical characteristics of the Healthcare sector company's recent price action.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is PFE stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), PFE is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is PFE's TickrTrends verdict?

PFE's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does PFE compare to other Healthcare stocks?

PFE ranks #101 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is PFE overbought or oversold?

PFE's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

PFE vs AMGN · PFE vs BMY · PFE vs CAH · PFE vs CNC · PFE vs CRL